Join the club for FREE to access the whole archive and other member benefits.

Celine Halioua

CEO and founder of Loyal, interested in the biology of aging

Celine is the founder and CEO of Loyal, a biotech startup developing drugs to extend dog lifespan. She is also dabble in biotech & deep-tech investing.

Before that, she was a D.Phil. student at Oxford studying the health economics of gene therapy (St Peter’s College) & Chief of Staff to Laura Deming at Longevity Fund. Celine studied neuroscience and nanobiotechnology at the University of Texas at Austin and Uppsala Universitet in Sweden. She worked in the laboratories of Dr. Evan Snyder at the Sanford Consortium of Regenerative Medicine on novel enteric neuron disease therapeutics, and of Dr. Richard Morrisett and Dr. Keith Stevenson at The University of Texas at Austin on the development of a novel fluorescent silver-nanocluster-based neuronal tracers.

She is interested in biotechnology, specifically unravelling and developing therapeutics for pathological aging. Celine is also interested in healthcare systems, specifically the application of socialized healthcare practices to the United States and the economic incentivization of preventative and curative medicine.

Visit website: https://www.celinehh.com/

 celinehh

 celinehalioua

See also: Company Loyal - Biotechnology company developing medicines to extend dog lifespan

Details last updated 25-Aug-2021

Celine Halioua is also referenced in the following:

Forever Young?

Lara Lewington interviews scientists, commentators and a "professional rejuvenation athlete" (Bryan Johnson)

Longevity Investors Conference

27-Sep-2021

Online conference gathering longevity experts and investors at one place hosted by Marc P. Bernegger and Dr. Tobias Reichmuth

Nutrition and the biology of ageing

12-Sep-2022 to 14-Sep-2022

Event about nutrition and its impact on metabolism organized by British Society for Research on Ageing

Celine Halioua News

Loyal aims for a animal pharmaceutical company to delay ageing of "man's best friend"

TechCrunch - 23-Sep-2021

Developing therapies to extend life in dogs, and further extending the research in humans

Read more...